156 related articles for article (PubMed ID: 22449782)
21. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.
Khan S; Bijker MS; Weterings JJ; Tanke HJ; Adema GJ; van Hall T; Drijfhout JW; Melief CJ; Overkleeft HS; van der Marel GA; Filippov DV; van der Burg SH; Ossendorp F
J Biol Chem; 2007 Jul; 282(29):21145-59. PubMed ID: 17462991
[TBL] [Abstract][Full Text] [Related]
22. T-cell epitope peptide vaccines.
Elsawa SF; Rodeberg DA; Celis E
Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
[TBL] [Abstract][Full Text] [Related]
23. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity.
Heit A; Schmitz F; Haas T; Busch DH; Wagner H
Eur J Immunol; 2007 Aug; 37(8):2063-74. PubMed ID: 17628858
[TBL] [Abstract][Full Text] [Related]
24. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; van der Burg SH; Offringa R
Eur J Immunol; 2008 Apr; 38(4):1033-42. PubMed ID: 18350546
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of glycocluster-tumor antigenic peptide conjugates for dendritic cell targeting.
Srinivas O; Larrieu P; Duverger E; Boccaccio C; Bousser MT; Monsigny M; Fonteneau JF; Jotereau F; Roche AC
Bioconjug Chem; 2007; 18(5):1547-54. PubMed ID: 17602511
[TBL] [Abstract][Full Text] [Related]
26. Dendritic cell immunotherapy for the treatment of neoplastic disease.
Decker WK; Xing D; Shpall EJ
Biol Blood Marrow Transplant; 2006 Feb; 12(2):113-25. PubMed ID: 16443510
[TBL] [Abstract][Full Text] [Related]
27. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
28. The immunogenicity of CpG-antigen conjugates.
Wagner H
Adv Drug Deliv Rev; 2009 Mar; 61(3):243-7. PubMed ID: 19174176
[TBL] [Abstract][Full Text] [Related]
29. TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients.
Zom GG; Welters MJ; Loof NM; Goedemans R; Lougheed S; Valentijn RR; Zandvliet ML; Meeuwenoord NJ; Melief CJ; de Gruijl TD; Van der Marel GA; Filippov DV; Ossendorp F; Van der Burg SH
Oncotarget; 2016 Oct; 7(41):67087-67100. PubMed ID: 27564262
[TBL] [Abstract][Full Text] [Related]
30. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
[TBL] [Abstract][Full Text] [Related]
32. IRX-2 increases the T cell-specific immune response to protein/peptide vaccines.
Naylor PH; Hernandez KE; Nixon AE; Brandwein HJ; Haas GP; Wang CY; Hadden JW
Vaccine; 2010 Oct; 28(43):7054-62. PubMed ID: 20708999
[TBL] [Abstract][Full Text] [Related]
33. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
34. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cells: tools and targets for antitumor vaccination.
den Brok MH; Nierkens S; Figdor CG; Ruers TJ; Adema GJ
Expert Rev Vaccines; 2005 Oct; 4(5):699-710. PubMed ID: 16221071
[TBL] [Abstract][Full Text] [Related]
36. [Dendritic cell-based cancer immunotherapy].
Aruga A
Nihon Rinsho; 2010 Jun; 68(6):1107-10. PubMed ID: 20535963
[TBL] [Abstract][Full Text] [Related]
37. Composite peptide-based vaccines for cancer immunotherapy (Review).
Yang J; Zhang Q; Li K; Yin H; Zheng JN
Int J Mol Med; 2015 Jan; 35(1):17-23. PubMed ID: 25395173
[TBL] [Abstract][Full Text] [Related]
38. [Basic background for adjuvant immunotherapy].
Seya T
Nihon Rinsho; 2012 Dec; 70(12):2059-65. PubMed ID: 23259375
[TBL] [Abstract][Full Text] [Related]
39. Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability.
Moynihan KD; Holden RL; Mehta NK; Wang C; Karver MR; Dinter J; Liang S; Abraham W; Melo MB; Zhang AQ; Li N; Gall SL; Pentelute BL; Irvine DJ
Cancer Immunol Res; 2018 Sep; 6(9):1025-1038. PubMed ID: 29915023
[TBL] [Abstract][Full Text] [Related]
40. Immune system targeting by biodegradable nanoparticles for cancer vaccines.
Silva JM; Videira M; Gaspar R; Préat V; Florindo HF
J Control Release; 2013 Jun; 168(2):179-99. PubMed ID: 23524187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
